The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel
Open accessAbstract
BACKGROUND: Next‐generation sequencing (NGS) allows for simultaneous sequencing of multiple cancer susceptibility genes and, for an individual, may be more efficient and less expensive than sequential testing. The authors assessed the frequency of deleterious germline mutations among individuals with breast cancer who were referred for BRCA1 and BRCA2 (BRCA1/2) gene testing using a panel of 25 genes associated with inherited cancer predisposition. METHODS: This was a cross‐sectional study using NGS in 2158 individuals, including 1781 who were referred for commercial BRCA1/2 gene testing (cohort 1) and 377 who had detailed personal and family history and had previously tested negative for BRCA1/2 mutations (cohort 2). RESULTS: Mutations were identified in 16 genes, most frequently in BRCA1, BRCA2, CHEK2, ATM, and PALB2. Among the participants in cohort 1, 9.3% carried a BRCA1/2 mutation, 3.9% carried a mutation in another breast/ovarian cancer susceptibility gene, and 0.3% carried an incidental mutation in another cancer susceptibility gene unrelated to breast or ovarian cancer. In cohort 2, the frequency of mutations in breast/ovarian‐associated genes other than BRCA1/2 was 2.9%, and an additional 0.8% had an incidental mutation. In cohort 1, Lynch syndrome‐related mutations were identified in 7 individuals. In contrast to BRCA1/2 mutations, neither age at breast cancer diagnosis nor family history of ovarian or young breast cancer predicted for other mutations. The frequency of mutations in genes other than BRCA1/2 was lower in Ashkenazi Jews compared with non‐Ashkenazi individuals (P=.026). CONCLUSIONS: Using an NGS 25‐gene panel, the frequency of mutations in genes other than BRCA1/2 was 4.3%, and most mutations (3.9%) were identified in genes associated with breast/ovarian cancer. Cancer 2015;121:25–33. © 2014 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,841
The CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
The Breast Cancer Susceptibility Collaboration (UK), Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., Reid, S., Spanova, K., Barfoot, R., et al. (2007) · Nature Genetics · doi:10.1038/ng1959 · Cited by 1,003
Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., Roeb, W., Agnew, K. J., Stray, S. M., Wickramanayake, A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115052108 · Cited by 933
Lifetime Cancer Risks in Individuals with Germline PTEN Mutations
Tan, M.-H., Mester, J. L., Ngeow, J., Rybicki, L. A., Orloff, M. S., & Eng, C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2283 · Cited by 892
Frequency and Spectrum of Cancers in the Peutz-Jeghers Syndrome
Hearle, N., Schumacher, V., Menko, F. H., Olschwang, S., Boardman, L. A., Gille, J. J. P., Keller, J. J., Westerman, A. M., Scott, R. J., Lim, W., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0083 · Cited by 855
Richards, C. S., Bale, S., Bellissimo, D. B., Das, S., Grody, W. W., Hegde, M. R., Lyon, E., & Ward, B. E. (2008) · Genetics in Medicine · doi:10.1097/gim.0b013e31816b5cae · Cited by 832
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826
Frank, T. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1480 · Cited by 812
Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J.-W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303108 · Cited by 784 · cited 1×
“Identifying a PALB2 or CDK2NA mutation in a patient with a family history of pancreatic cancer may prompt pancreatic cancer surveillance.(50) Multigene panel testing identifies several kinds of VUS, which clinicians should anticipate and be prepared to address with their patients.”
BackgroundDetermining Carrier Probabilities for Breast Cancer–Susceptibility Genes BRCA1 and BRCA2
Parmigiani, G., Berry, D. A., & Aguilar, O. (1998) · The American Journal of Human Genetics · doi:10.1086/301670 · Cited by 753
The Breast Cancer Susceptibility Collaboration (UK), Seal, S., Thompson, D., Renwick, A., Elliott, A., Kelly, P., Barfoot, R., Chagtai, T., Jayatilake, H., Ahmed, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1902 · Cited by 746
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles
The Breast Cancer Susceptibility Collaboration (UK), Renwick, A., Thompson, D., Seal, S., Kelly, P., Chagtai, T., Ahmed, M., North, B., Jayatilake, H., Barfoot, R., et al. (2006) · Nature Genetics · doi:10.1038/ng1837 · Cited by 743
Meindl, A., Hellebrand, H., Wiek, C., Erven, V., Wappenschmidt, B., Niederacher, D., Freund, M., Lichtner, P., Hartmann, L., Schaal, H., et al. (2010) · Nature Genetics · doi:10.1038/ng.569 · Cited by 743
Pharoah, P. D. P., Guilford, P., & Caldas, C. (2001) · Gastroenterology · doi:10.1053/gast.2001.29611 · Cited by 638
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., Han, J. H., Lowstuter, K., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 609
Frank, T. S., Deffenbaugh, A. M., Reid, J. E., Hulick, M., Ward, B. E., Lingenfelter, B., Gumpper, K. L., Scholl, T., Tavtigian, S. V., Pruss, D. R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1480 · Cited by 558
Multiple Primary Cancers in Families With Li-Fraumeni Syndrome
Hisada, M., Garber, J. E., Li, F. P., Fung, C. Y., & Fraumeni, J. F. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.606 · Cited by 557
Self-citationCancer Risks and Mortality in Heterozygous ATM Mutation Carriers
Thompson, D., Duedal, S., Kirner, J., McGuffog, L., Last, J., Reiman, A., Byrd, P., Taylor, M., & Easton, D. F. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji141 · Cited by 543
Germline mutations in RAD51D confer susceptibility to ovarian cancer
Breast Cancer Susceptibility Collaboration (UK), Loveday, C., Turnbull, C., Ramsay, E., Hughes, D., Ruark, E., Frankum, J. R., Bowden, G., Kalmyrzaev, B., Warren-Perry, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.893 · Cited by 534
Walsh, T., Lee, M. K., Casadei, S., Thornton, A. M., Stray, S. M., Pennil, C., Nord, A. S., Mandell, J. B., Swisher, E. M., & King, M.-C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007983107 · Cited by 487
(2004) · The American Journal of Human Genetics · doi:10.1086/421251 · Cited by 471
Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric Cancer
Kaurah, P., MacMillan, A., Boyd, N., Senz, J., De Luca, A., Chun, N., Suriano, G., Zaor, S., Van Manen, L., Gilpin, C., et al. (2007) · JAMA · doi:10.1001/jama.297.21.2360 · Cited by 447
Mutations in BRIP1 confer high risk of ovarian cancer
Rafnar, T., Gudbjartsson, D. F., Sulem, P., Jonasdottir, A., Sigurdsson, A., Jonasdottir, A., Besenbacher, S., Lundin, P., Stacey, S. N., Gudmundsson, J., et al. (2011) · Nature Genetics · doi:10.1038/ng.955 · Cited by 406
Probability of Carrying a Mutation of Breast-Ovarian Cancer Gene BRCA1 Based on Family History
Berry, D. A., Parmigiani, G., Sanchez, J., Schildkraut, J., & Winer, E. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.3.227 · Cited by 380
p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis
Kemp, C. J., Wheldon, T., & Balmain, A. (1994) · Nature Genetics · doi:10.1038/ng0994-66 · Cited by 368
Pilarski, R., & Eng, C. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.018036 · Cited by 329
Weischer, M., Bojesen, S. E., Ellervik, C., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5922 · Cited by 306
Weston, V. J., Oldreive, C. E., Skowronska, A., Oscier, D. G., Pratt, G., Dyer, M. J. S., Smith, G., Powell, J. E., Rudzki, Z., Kearns, P., et al. (2010) · Blood · doi:10.1182/blood-2010-01-265769 · Cited by 300
Relative frequency and morphology of cancers in STK11 mutation carriers1 ☆
Lim, W., Olschwang, S., Keller, J. J., Westerman, A. M., Menko, F. H., Boardman, L. A., Scott, R. J., Trimbath, J., Giardiello, F. M., & Gruber, S. B. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.014 · Cited by 254
Cybulski, C., Wokołorczyk, D., Jakubowska, A., Huzarski, T., Byrski, T., Gronwald, J., Masojć, B., Dębniak, T., Górski, B., Blecharz, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0778 · Cited by 254
Germline RAD51C mutations confer susceptibility to ovarian cancer
Breast Cancer Susceptibility Collaboration (BCSC) (UK), Loveday, C., Turnbull, C., Ruark, E., Xicola, R. M. M., Ramsay, E., Hughes, D., Warren-Perry, M., Snape, K., Eccles, D., et al. (2012) · Nature Genetics · doi:10.1038/ng.2224 · Cited by 252
Contribution of Inherited Mutations in the BRCA2-Interacting Protein PALB2 to Familial Breast Cancer
Casadei, S., Norquist, B. M., Walsh, T., Stray, S., Mandell, J. B., Lee, M. K., Stamatoyannopoulos, J. A., & King, M.-C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3958 · Cited by 240
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
Dedes, K. J., Wilkerson, P. M., Wetterskog, D., Weigelt, B., Ashworth, A., & Reis-Filho, J. S. (2011) · Cell Cycle · doi:10.4161/cc.10.8.15273 · Cited by 191
Eggington, J. M., Bowles, K. R., Moyes, K., Manley, S., Esterling, L., Sizemore, S., Rosenthal, E., Theisen, A., Saam, J., Arnell, C., et al. (2014) · Clinical Genetics · doi:10.1111/cge.12315 · Cited by 188
Self-citationJenkins, M. A., Croitoru, M. E., Monga, N., Cleary, S. P., Cotterchio, M., Hopper, J. L., & Gallinger, S. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0793 · Cited by 177
Two metachronous tumors in the radiotherapy fields of a patient with Li‐Fraumeni syndrome
Limacher, J., Frébourg, T., Natarajan‐Amé, S., & Bergerat, J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1021 · Cited by 151
Heikkinen, T., Kärkkäinen, H., Aaltonen, K., Milne, R. L., Heikkilä, P., Aittomäki, K., BLOMQVIST, C. P., & Nevanlinna, H. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3128 · Cited by 144
Nijmegen Breakage Syndrome mutations and risk of breast cancer
Bogdanova, N. V., Feshchenko, S., Schürmann, P., Waltes, R., Wieland, B., Hillemanns, P., Rogov, Y., Dammann, O., Bremer, M., Karstens, J. H., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23168 · Cited by 143
Increased Colorectal Cancer Incidence in Obligate Carriers of Heterozygous Mutations in MUTYH
Jones, N., Vogt, S. L., Nielsen, M., Christian, D., Wark, P. A., Eccles, D., Edwards, E., Evans, D. G., Maher, E. R., Vasen, H. F. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.047 · Cited by 132
A PALB2 mutation associated with high risk of breast cancer
Southey, M. C., Teo, Z. L., Dowty, J. G., Odefrey, F., Park, D. J., Tischkowitz, M. D., Sabbaghian, N., Apicella, C., Byrnes, G. B., Winship, I., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2796 · Cited by 118
Osório, A., Endt, D., Fernández, F., Eirich, K., de la Hoya, M., Schmutzler, R. K., Caldés, T., Meindl, A., Schindler, D., & Benitez, J. J. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds115 · Cited by 99
Cancer Risk of Heterozygotes With the NBN Founder Mutation
Seemanová, E., Jarolı́m, P., Seeman, P., Varon, R., Digweed, M., Swift, M., & Sperling, K. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm251 · Cited by 96
Cancer predisposing BARD1 mutations in breast–ovarian cancer families
Ratajska, M., Antoszewska, E., Piskorz, A., Brożek, I., Borg, Å., Kusmierek, H., Biernat, W., & Limon, J. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1403-8 · Cited by 96
Brakeleer, S. D., Grève, J. D., Loris, R., Janin, N., Lissens, W., Sermijn, E., & Teugels, E. (2010) · Human Mutation · doi:10.1002/humu.21200 · Cited by 89
Rare germline mutations inPALB2and breast cancer risk: A population-based study
Tischkowitz, M. D., Capanu, M., Sabbaghian, N., Li, L., Liang, X., Vallée, M., Tavtigian, S. V., CONCANNON, P. J., Foulkes, W. D., Bernstein, L., et al. (2012) · Human Mutation · doi:10.1002/humu.22022 · Cited by 86
Desjardins, S., Beauparlant, J. C., Labrie, Y., Ouellette, G., BRCAs, I., & Durocher, F. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-181 · Cited by 37
Germline PALB2 mutation analysis in breast–pancreas cancer families: Table 1
Stadler, Z. K., Salo‐Mullen, E. E., Sabbaghian, N., Simon, J. A., Zhang, L., Olson, S. H., Kurtz, R. C., Offit, K., Foulkes, W. D., Robson, M. E., et al. (2011) · Journal of Medical Genetics · doi:10.1136/jmg.2010.087379 · Cited by 30
Cited by
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., & Lindor, N. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0996 · Cited by 934
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer
Couch, F. J., Shimelis, H., Hu, C., Hart, S. N., Polley, E. C., Na, J., Hallberg, E., Moore, R., Thomas, A., Lilyquist, J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0424 · Cited by 611
Tung, N., Lin, N. U., Kidd, J., Allen, B. A., Singh, N., Wenstrup, R. J., Hartman, A.-R., Winer, E. P., & Garber, J. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.0747 · Cited by 556
Self-citationPatel, K. N., Yip, L., Lubitz, C. C., Grubbs, E. G., Miller, B. S., Shen, W., Angelos, P., Chen, H., Doherty, G. M., Fahey, T. J., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003580 · Cited by 541
[Retracted] Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures
Kashyap, D., Pal, D., Sharma, R., Garg, V. K., Goel, N., Koundal, D., Zaguia, A., Koundal, S., & Belay, A. (2022) · BioMed Research International · doi:10.1155/2022/9605439 · Cited by 529
Retracted
Metadata
- Authors
- Tung, N., Battelli, C., Allen, B., Kaldate, R., Bhatnagar, S., Bowles, K., Timms, K., Garber, J. E., Herold, C., Ellisen, L., Krejdovsky, J., DeLeonardis, K., Sedgwick, K., Soltis, K., Roa, B., Wenstrup, R. J., & Hartman, A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2014-09-03
- Volume
- 121
- Issue
- 1
- Pages
- 25-33
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1588589870
- Cited by
- 430
- References
- 49
- FWCI
- 29.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.